摘要
目的 探讨经导管肝动脉灌注化疗(HAIC)联合靶向及免疫治疗晚期肝细胞肝癌的疗效及安全性。方法 选取2021年5月至2021年12月在赣州市人民医院肿瘤科进行治疗的60例晚期肝细胞癌患者,随机分为观察组与对照组,每组各30例,对照组采用靶向及免疫治疗,观察组采用HAIC联合靶向及免疫治疗。对比两组患者的客观缓解率、疾病控制率、总生存期、无进展生存期及不良反应发生情况。结果 观察组与对照组客观缓解率差异无统计学意义(26.7%vs. 13.3%,P=0.196),观察组疾病控制率高于对照组(86.7%vs. 53.3%,P=0.004)。观察组总生存期[(15.74±2.94)月vs.(13.28±2.69)月,P=0.024]、无进展生存期[(9.74±1.74)月vs.(8.02±1.46)月,P=0.007]长于对照组。观察组与对照组不良反应发生率差异无统计学意(16.67%vs.23.33%,P=0.518)。结论 使用HAIC联合靶向及免疫治疗可以控制肝细胞癌进展,延长生存期。
Objective To investigate the efficacy and safety of transcatheter hepatic artery infusion chemotherapy(HAIC)combined with targeted and immunotherapy in the treatment of advanced hepatocellular hepatocellular carcinoma.Methods A total of 60 patients with advanced hepatocellular carcinoma who were treated in the Department of Oncology of Ganzhou People's Hospital from May 2021 to December 2021 were selected and randomly divided into an observation group and a control group,with 30 cases in each group;the control group was treated with targeted and immunotherapy,and the observation group was treated with HAIC combined with targeted and immunotherapy.The objective remission rate,disease control rate,overall survival,progression-free survival and the occurrence of adverse reactions were compared between the two groups.Results The difference in objective remission rate between the observation group and the control group was not statistically significant(26.7%vs.13.3%,P=0.196),and the disease control rate of the observation group was higher than that of the control group(86.7%vs.53.3%,P=0.004).Overall survival(15.74±2.94 months vs.13.28±2.69 months,P=0.024)and progression-free survival(9.74±1.74 months vs.8.02±1.46 months,P=0.007)were longer in the observation group than in the control group.The difference in the incidence of adverse reactions between the observation and control groups was not statistically significant(16.7%vs.23.3%,P=0.518).Conclusions The use of HAIC combined with targeted and immunotherapy can control the progression of hepatocellular carcinoma and prolong survival.
作者
黄骏骢
丁于海
温时来
李廷
钟琼
HUANG Juncong;DING Yuhai;WEN Shiai;LI Ting;ZHONG Qiong(Department of Oncology,Ganzhou People's Hospital,Ganzhou 341000)
出处
《中国医药指南》
2023年第28期80-82,共3页
Guide of China Medicine
基金
赣州市科技计划项目(GZ2021ZSF139)。
关键词
经导管肝动脉灌注化疗
肝癌
疗效
Hepatic artery infusion chemotherapy
Liver cancer
Efficacy
